Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 71%
Buy 0%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Veracyte is a diagnostics company specializing in tests for various types of cancer, with a strong portfolio of tests for prostate, thyroid, breast, and bladder cancer. With validated tests and strong clinical evidence, the company has the potential to capture market share from larger competitors in the space. Additionally, the company's planned entry into the $15 billion minimal residual disease market with its TrueMRD platform and its strong revenue growth potential support a positive outlook for this stock.

Bears say

Veracyte is a genomic diagnostics company with a focus on cancer testing. Although the company offers tests for various types of cancer, including prostate, thyroid, breast, and bladder cancer, its revenue growth may be unsustainable, with risks such as weaker-than-expected sales and margins. The company's 12-month price target of $48 is based on an EV/sales multiple of 5.5x, which is above its industry peers' multiples. However, there is potential for upside to revenue and earnings estimates due to the company's innovative testing practices.

Veracyte (VCYT) has been analyzed by 7 analysts, with a consensus rating of Buy. 71% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 7 analysts, Veracyte (VCYT) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.